BIOMAT Database Logo BIOMAT Database Logo

CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. 2006

J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
Laboratoire de Biologie Médicale, Centre GF. Leclerc, Dijon, France. jriedinger@dijon.fnclcc.fr

BACKGROUND CA 125 assays enable treatment-response monitoring in ovarian cancer. METHODS A multicentric study of CA 125 kinetics under induction chemotherapy was performed in 631 patients. CA 125 half-life was calculated by mono-compartmental logarithmic regression. Nadir CA 125 concentration and time to nadir were also studied. Survival analyses for disease-free survival (DFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) models. RESULTS For 553 stage IIC-IV patients, 459 (83.0%) relapsed and 444 (80.3%) died from cancer. Median (range) follow up time was 32 months (2-214 months). Median (range) for CA 125 kinetics were: 263 kU/l (5-52000 kU/l) before 1st course, 15.8 days (4.5-417.9 days) for CA 125 half-life, 16 kU/l (3-2610 kU/l) for nadir and 85 days (0-361 days) for time to nadir. Pre-chemotherapy CA 125, its half-life, nadir concentration and time to nadir all had a univariate prognostic value for DFS and OS (P<0.0001). In Cox models, CA 125 half-life, residual tumour (P<0.0001 for both), nadir concentration (P=0.0002) and stage (P=0.0118) were the most powerful prognostic factors for DFS. For OS, the significant variables were similar, with age ranking last (P=0.0319). CONCLUSIONS Among well-established prognostic factors in ovarian cancers, CA 125 half-life and nadir concentration bear a strong and independent prognostic value.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
July 1995, Gynecologic oncology,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
September 2009, Journal of surgical oncology,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer.
April 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
[Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
March 2007, Bulletin du cancer,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
CA 125 half-life in ovarian cancer: a multivariate survival analysis.
June 1993, British journal of cancer,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma.
January 1990, Acta obstetricia et gynecologica Scandinavica,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
CA-125 monitoring during chemotherapy for ovarian cancer.
January 1986, The International journal of biological markers,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
[Prognostic significance of the CA 125 half-life for the further outcome of ovarian cancer].
September 1992, Geburtshilfe und Frauenheilkunde,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
[CA 125 in epithelial ovarian cancer].
May 1998, Ugeskrift for laeger,
J M Riedinger, and J Wafflart, and G Ricolleau, and N Eche, and H Larbre, and J P Basuyau, and I Dalifard, and K Hacene, and M F Pichon
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.
February 2008, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!